PHIO — Phio Pharmaceuticals Corp.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1533040 ·
Last close
$0.72
Market Cap
$8.57M
52W High
$1.88
52W Low
$0.70
ADV30
69,655
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -4,268,000 -4,160,000 11,317,000 10,609,000 2,697,000
Jun 2026 0 — -4,268,000 -4,138,000 14,307,000 12,996,000 1,705,000
Mar 2026 0 — -4,167,000 -4,003,000 17,412,000 17,031,000 950,000
Dec 2025 0 — -2,534,000 -2,371,000 21,487,000 21,031,000 1,340,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-12,202,000
Investing CF
$-4,000
Financing CF
$14,427,000
CapEx
$-12,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.59
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-163,195,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-13,474,000
Pretax Income TTM
$-12,904,000
Interest Exp TTM
—
Analysts
1

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -9,220,000 -8,698,000 21,487,000 1,340,000 20,147,000 -7,979,000
Dec 2024 0 -7,387,000 -7,150,000 5,738,000 1,015,000 4,723,000 -7,112,000
Dec 2023 0 -10,698,000 -10,826,000 9,364,000 1,634,000 7,730,000 -10,749,000
Dec 2022 0 -11,462,000 -11,480,000 12,814,000 1,976,000 10,838,000 -12,129,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-12,904,000
OpCashFlow TTM
—
Assets (Latest)
$14,307,000
Forward EPS
$-0.61

Peers — same industry

TickerNameMarket CapLastDaily %
DARE Dare Bioscience, Inc. $8.44M $0.43 —
CALC CalciMedica, Inc. $8.41M $1.22 —
LEXX Lexaria Bioscience Corp. $8.81M $4.18 —
VTGN Vistagen Therapeutics, Inc. $8.34M $0.19 —
BFRI Biofrontera Inc. $8.81M $0.59 —

News headlines (Yahoo Finance, 1h cache)

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
2026-11-12 12:00 · Yahoo
Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
2026-11-09 12:00 · Yahoo
Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
2026-11-06 17:21 · Yahoo
Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
2026-11-06 14:05 · Yahoo
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
2026-10-19 13:53 · Yahoo
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
2026-10-13 11:00 · Yahoo
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
2026-10-06 11:00 · Yahoo
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
2026-10-05 11:00 · Yahoo
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
2026-09-23 11:00 · Yahoo
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
2026-09-14 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.